130 related articles for article (PubMed ID: 16150195)
21. Additive effects of raloxifene and alendronate on bone density and biochemical markers of bone remodeling in postmenopausal women with osteoporosis.
Johnell O; Scheele WH; Lu Y; Reginster JY; Need AG; Seeman E
J Clin Endocrinol Metab; 2002 Mar; 87(3):985-92. PubMed ID: 11889149
[TBL] [Abstract][Full Text] [Related]
22. Efficacy of teriparatide in increasing bone mineral density in postmenopausal women with osteoporosis--an Indian experience.
Sethi BK; Chadha M; Modi KD; Kumar KM; Mehrotra R; Sriram U
J Assoc Physicians India; 2008 Jun; 56():418-24. PubMed ID: 18822620
[TBL] [Abstract][Full Text] [Related]
23. Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study.
McClung MR; O'Donoghue ML; Papapoulos SE; Bone H; Langdahl B; Saag KG; Reid IR; Kiel DP; Cavallari I; Bonaca MP; Wiviott SD; de Villiers T; Ling X; Lippuner K; Nakamura T; Reginster JY; Rodriguez-Portales JA; Roux C; Zanchetta J; Zerbini CAF; Park JG; Im K; Cange A; Grip LT; Heyden N; DaSilva C; Cohn D; Massaad R; Scott BB; Verbruggen N; Gurner D; Miller DL; Blair ML; Polis AB; Stoch SA; Santora A; Lombardi A; Leung AT; Kaufman KD; Sabatine MS;
Lancet Diabetes Endocrinol; 2019 Dec; 7(12):899-911. PubMed ID: 31676222
[TBL] [Abstract][Full Text] [Related]
24. [Effects of Migu Tablet on bone mineral density, serum levels of osteoprotegerin and its ligand and bone metabolic markers in patients with postmenopausal osteoporosis].
Dai Y; Shen L; Yang YP
Zhongguo Zhong Xi Yi Jie He Za Zhi; 2007 Aug; 27(8):696-9. PubMed ID: 17879531
[TBL] [Abstract][Full Text] [Related]
25. [Effect of raloxifene hydrochloride on bone mineral density, bone metabolism and serum lipids in Chinese postmenopausal women with osteoporosis].
Liu JL; Zhu HM; Huang QR; Zhang ZL; Li HL; Qin YJ; Zhang Y; Wei DL; Lu JH; Liu H; Chen XP; Liu YJ; Ekangaki A; Zheng YM; Diez-Perez A; Harpe K
Zhonghua Yi Xue Za Zhi; 2004 Feb; 84(4):269-73. PubMed ID: 15059505
[TBL] [Abstract][Full Text] [Related]
26. Safety and efficacy of teriparatide in elderly women with established osteoporosis: bone anabolic therapy from a geriatric perspective.
Boonen S; Marin F; Mellstrom D; Xie L; Desaiah D; Krege JH; Rosen CJ
J Am Geriatr Soc; 2006 May; 54(5):782-9. PubMed ID: 16696744
[TBL] [Abstract][Full Text] [Related]
27. Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women.
Murphy MG; Weiss S; McClung M; Schnitzer T; Cerchio K; Connor J; Krupa D; Gertz BJ;
J Clin Endocrinol Metab; 2001 Mar; 86(3):1116-25. PubMed ID: 11238495
[TBL] [Abstract][Full Text] [Related]
28. [Prevention and treatment of aromatase inhibitor-associated bone loss by shugan jiangu recipe in postmenopausal women with breast cancer: a clinical study].
Li YQ; Sun H; Xue D; Xu YC; Li ZD; Wang W; Li PP
Zhongguo Zhong Xi Yi Jie He Za Zhi; 2014 Sep; 34(9):1064-8. PubMed ID: 25335329
[TBL] [Abstract][Full Text] [Related]
29. Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Fosamax International Trial Study Group.
Pols HA; Felsenberg D; Hanley DA; Stepán J; Muñoz-Torres M; Wilkin TJ; Qin-sheng G; Galich AM; Vandormael K; Yates AJ; Stych B
Osteoporos Int; 1999; 9(5):461-8. PubMed ID: 10550467
[TBL] [Abstract][Full Text] [Related]
30. [Effects of yigu capsule containing serum on the osteoblast differentiation and the expressions of osteoprotegerin and bone morphogenetic protein 2 after treatment by advanced glycation end products in vitro].
Zhu XF; Wang TC; Zhang RH
Zhongguo Zhong Xi Yi Jie He Za Zhi; 2012 Apr; 32(4):525-9. PubMed ID: 22803437
[TBL] [Abstract][Full Text] [Related]
31. Comparison of different treatment modalities for postmenopausal patients with osteopenia: hormone replacement therapy, calcitonin and clodronate.
Tiraş MB; Noyan V; Yildiz A; Biberoğlu K
Climacteric; 2000 Jun; 3(2):92-101. PubMed ID: 11910657
[TBL] [Abstract][Full Text] [Related]
32. Effect of low-dose alendronate treatment on bone mineral density and bone turnover markers in Chinese postmenopausal women with osteopenia and osteoporosis.
Li M; Zhang ZL; Liao EY; Chen DC; Liu J; Tao TZ; Wu W; Xia WB; Lu YJ; Sheng ZF; Lu CY; Meng GL; Xu L; Zhang WJ; Hu YY; Xu L
Menopause; 2013 Jan; 20(1):72-8. PubMed ID: 22968256
[TBL] [Abstract][Full Text] [Related]
33. Comparison of parathyroid hormone (1-34) and elcatonin in postmenopausal women with osteoporosis: an 18-month randomized, multicenter controlled trial in China.
Li Y; Xuan M; Wang B; Yang J; Zhang H; Zhang XZ; Guo XH; Lü XF; Xue QY; Yang GY; Ji QH; Liu ZM; Li CJ; Wu TF; Sheng ZY; Li PQ; Tong JC
Chin Med J (Engl); 2013 Feb; 126(3):457-63. PubMed ID: 23422107
[TBL] [Abstract][Full Text] [Related]
34. [Clinical study on combination of multiple regimens in treatment of osteoporosis in perimenopause and postmenopausal women].
Guan YT; Cai LL; Ding HX; Chen GD; Hu Y
Zhonghua Fu Chan Ke Za Zhi; 2010 Aug; 45(8):571-4. PubMed ID: 21029610
[TBL] [Abstract][Full Text] [Related]
35. Five-year follow-up study of a kidney-tonifying herbal Fufang for prevention of postmenopausal osteoporosis and fragility fractures.
Deng WM; Zhang P; Huang H; Shen YG; Yang QH; Cui WL; He YS; Wei S; Ye Z; Liu F; Qin L
J Bone Miner Metab; 2012 Sep; 30(5):517-24. PubMed ID: 22722637
[TBL] [Abstract][Full Text] [Related]
36. A randomized study of tibolone on bone mineral density in osteoporotic postmenopausal women with previous fractures.
Studd J; Arnala I; Kicovic PM; Zamblera D; Kröger H; Holland N
Obstet Gynecol; 1998 Oct; 92(4 Pt 1):574-9. PubMed ID: 9764631
[TBL] [Abstract][Full Text] [Related]
37. Increased bone mineral density for 1 year of romosozumab, vs placebo, followed by 2 years of denosumab in the Japanese subgroup of the pivotal FRAME trial and extension.
Miyauchi A; Dinavahi RV; Crittenden DB; Yang W; Maddox JC; Hamaya E; Nakamura Y; Libanati C; Grauer A; Shimauchi J
Arch Osteoporos; 2019 Jun; 14(1):59. PubMed ID: 31168657
[TBL] [Abstract][Full Text] [Related]
38. Effects of genistein and hormone-replacement therapy on bone loss in early postmenopausal women: a randomized double-blind placebo-controlled study.
Morabito N; Crisafulli A; Vergara C; Gaudio A; Lasco A; Frisina N; D'Anna R; Corrado F; Pizzoleo MA; Cincotta M; Altavilla D; Ientile R; Squadrito F
J Bone Miner Res; 2002 Oct; 17(10):1904-12. PubMed ID: 12369794
[TBL] [Abstract][Full Text] [Related]
39. Response rate of bone mineral density to teriparatide in postmenopausal women with osteoporosis.
Gallagher JC; Rosen CJ; Chen P; Misurski DA; Marcus R
Bone; 2006 Dec; 39(6):1268-75. PubMed ID: 16884968
[TBL] [Abstract][Full Text] [Related]
40. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group.
Harris ST; Watts NB; Genant HK; McKeever CD; Hangartner T; Keller M; Chesnut CH; Brown J; Eriksen EF; Hoseyni MS; Axelrod DW; Miller PD
JAMA; 1999 Oct; 282(14):1344-52. PubMed ID: 10527181
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
